Pharma & Biotech
The broker kicked off its US coverage of the stock with a US$45 a share valuation
07.57 Thu 09 Jul 2020
Genprex gene therapy candidate Oncoprex fast-tracking for non-small cell lung cancer treatment
TRACON Pharmaceuticals driving the development of targeted therapies for cancer
ImmunoPrecise Antibodies expecting significant revenue growth in 2019
Only registered members can use this feature.
Copyright © Proactive Investors 2019.
All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC.